NewGenIvf Group Limited (NIVFW)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NewGenIvf Group Limited (NIVFW) trades at $0.02. NewGenIvf Group Limited is an investment holding company providing assisted reproductive services in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. Market cap: $56,617, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for NIVFW: NIVFW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NIVFW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NIVFW: 1/1 perspectives are bearish.
How is this calculated? →NewGenIvf Group Limited (NIVFW) Healthcare & Pipeline Overview
NewGenIvf Group Limited offers fertility treatment solutions, including IVF and related services, in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company provides comprehensive care through its clinics, addressing the growing demand for assisted reproductive technologies in the region with a focus on personalized treatment plans.
What Is the Investment Thesis for NIVFW?
NewGenIvf Group Limited presents a focused investment opportunity within the assisted reproductive technology (ART) sector. The company's high profit margin of 653.9% indicates strong operational efficiency, although the gross margin of 18.7% suggests potential areas for improvement in cost management. Growth catalysts include expanding its clinic network and increasing service offerings in existing markets. The company's presence in Thailand, Cambodia, Hong Kong, and Kyrgyzstan provides geographic diversification. Key risks include regulatory changes in the healthcare sector and competition from established players. The company's P/E ratio of 0.07 suggests it may be undervalued relative to its earnings, but further due diligence is needed to assess long-term sustainability and growth potential.
Based on FMP financials and quantitative analysis
NIVFW Key Highlights
- Profit Margin of 653.9% indicates high profitability from its operations.
- P/E Ratio of 0.07 suggests a potentially undervalued stock relative to its earnings.
- Presence in four countries (Thailand, Cambodia, Hong Kong, and Kyrgyzstan) provides geographic diversification.
- Offers a comprehensive suite of fertility treatment solutions, including IVF, ICSI, and surrogacy services.
- Founded in 2010, indicating over a decade of experience in the assisted reproductive technology (ART) sector.
Who Are NIVFW's Competitors?
NIVFW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BFRG Bullfrog AI Holdings, Inc. Common Stock | $0.72 | +3.54% | $8.46M | — |
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 | |
| NWKHY Netcare Limited | $7.17 | +0.00% | $843.64M | 50 |
| AONC American Oncology Network, Inc. | $10.00 | +0.00% | $292.48M | 50 |
| DCGO DocGo Inc. | $0.59 | +5.81% | $58.07M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NIVFW's Key Strengths?
- Comprehensive range of fertility services.
- Established presence in multiple countries.
- High profit margin.
- Value-added services enhance patient experience.
What Are NIVFW's Weaknesses?
- Relatively small number of employees (76).
- Gross margin could be improved.
- Limited brand recognition compared to larger competitors.
- Dependence on specific geographic markets.
What Could Drive NIVFW Stock Higher?
- Expansion into new geographic markets, such as Vietnam or Indonesia, to tap into growing demand for fertility services.
- Increasing adoption of advanced reproductive technologies, such as preimplantation genetic testing (PGT), to improve success rates.
- Strategic partnerships with international clinics to attract more international patients.
- Implementation of telemedicine services to reach patients in remote areas and improve accessibility.
What Are the Key Risks for NIVFW?
- Financial-distress signal — its Altman Z-Score of 1.70 sits in the distress zone (elevated bankruptcy risk).
- Regulatory changes in the healthcare sector could impact the company's operations and profitability.
- Competition from established players could limit the company's market share and growth potential.
- Economic downturns could affect patient affordability and demand for fertility services.
- Fluctuations in exchange rates could impact the company's revenue from international patients.
What Are the Growth Opportunities for NIVFW?
- Expanding Clinic Network: NewGenIvf can grow by establishing new clinics in underserved markets within Southeast Asia and Central Asia. The market for fertility services in these regions is expanding, driven by increasing awareness and disposable incomes. A strategic expansion plan targeting key cities could significantly increase patient volume and revenue. The timeline for establishing new clinics is approximately 12-18 months per location, with a potential market size of several million dollars per clinic annually.
- Enhancing Service Offerings: The company can broaden its service portfolio to include more advanced reproductive technologies, such as preimplantation genetic testing (PGT) and advanced sperm selection techniques. These services cater to a higher-paying clientele and improve success rates, attracting more patients. The market for advanced reproductive technologies is growing rapidly, with a potential market size of millions of dollars annually. Implementation can begin within 6-12 months.
- Strategic Partnerships: Collaborating with international fertility clinics and research institutions can provide NewGenIvf with access to cutting-edge technologies and best practices. These partnerships can enhance the company's reputation and attract international patients seeking advanced treatments. The timeline for establishing strategic partnerships is approximately 6-9 months, with ongoing benefits in terms of technology transfer and patient referrals.
- Telemedicine and Remote Consultations: Implementing telemedicine services can expand NewGenIvf's reach to patients in remote areas and international clients. Remote consultations, online support groups, and virtual follow-up appointments can improve patient convenience and accessibility. The market for telemedicine is growing rapidly, with a potential market size of millions of dollars annually. Implementation can begin within 3-6 months.
- Marketing and Branding: Investing in targeted marketing campaigns to increase brand awareness and attract new patients. This includes online advertising, social media marketing, and participation in industry conferences. A strong brand presence can differentiate NewGenIvf from competitors and attract a larger patient base. The timeline for implementing marketing campaigns is ongoing, with continuous monitoring and optimization. The potential market reach is significant, with millions of potential patients accessible through digital channels.
What Opportunities Does NIVFW Have?
- Expanding clinic network in underserved markets.
- Enhancing service offerings with advanced technologies.
- Strategic partnerships with international clinics.
- Telemedicine and remote consultations to reach more patients.
What Threats Does NIVFW Face?
- Regulatory changes in the healthcare sector.
- Competition from established players.
- Economic downturns affecting patient affordability.
- Fluctuations in exchange rates impacting international patients.
What Are NIVFW's Competitive Advantages?
- Established presence in Thailand, Cambodia, Hong Kong, and Kyrgyzstan.
- Comprehensive range of fertility treatment services.
- Value-added services provide a holistic approach to patient care.
- Experienced medical professionals and staff.
What Does NIVFW Do?
Founded in 2010 and based in Bangkok, Thailand, NewGenIvf Group Limited operates as an investment holding company focused on providing assisted reproductive services. The company addresses the growing demand for fertility treatments by offering a range of solutions, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and embryo culture. These core services are supplemented by hormonal blood tests, infectious disease tests, chromosome screening, hysteroscopy, and sperm analysis, ensuring a comprehensive diagnostic and treatment approach. NewGenIvf also provides sperm sorting, washing, and freezing, as well as egg freezing, catering to diverse patient needs. Beyond the core IVF procedures, NewGenIvf offers surrogacy and ancillary caring services, providing regular body checks, vitamins, supplements, and medicines to surrogate mothers. The company enhances its treatment offerings with value-added services such as nutrition guidance, psychological counseling, acupuncture, and translation interpreters, aiming to provide holistic support to patients throughout their fertility journey. NewGenIvf delivers these services through its network of clinics located in Thailand, Cambodia, Hong Kong, and Kyrgyzstan, extending its reach to serve a broad international clientele seeking advanced reproductive technologies.
What Products and Services Does NIVFW Offer?
- Provides in vitro fertilization (IVF) services.
- Offers intracytoplasmic sperm injection (ICSI) services.
- Performs embryo culture.
- Conducts hormonal blood tests and infectious disease tests.
- Offers chromosome screening services.
- Provides surrogacy and ancillary caring services.
- Offers sperm analysis, sorting, washing, and freezing.
- Provides egg freezing services.
How Does NIVFW Make Money?
- Generates revenue from fertility treatment services, including IVF, ICSI, and related procedures.
- Earns income from surrogacy and ancillary caring services, such as providing care to surrogate mothers.
- Derives revenue from value-added services, including nutrition guidance, psychological counseling, and acupuncture.
- Operates clinics in Thailand, Cambodia, Hong Kong, and Kyrgyzstan, serving both local and international patients.
What Industry Does NIVFW Operate In?
The assisted reproductive technology (ART) industry is experiencing growth driven by increasing infertility rates, rising disposable incomes, and advancements in medical technology. The global fertility services market is projected to reach billions of dollars by 2030. NewGenIvf Group Limited operates in a competitive landscape that includes both local and international players. Competitors like ACON, BBLG, BFRG, BGMS, and BNBX offer similar services. NewGenIvf's success depends on its ability to differentiate through service quality, technology adoption, and geographic expansion.
Who Are NIVFW's Key Customers?
- Couples experiencing infertility issues.
- Individuals seeking fertility treatments.
- International patients seeking affordable and high-quality fertility services.
- Surrogate mothers requiring medical care and support.
F-Score 6/9Financial Health
NewGenIvf Group Limited's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.70 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project NewGenIvf Group Limited revenue of about $65.1M for fiscal 2026, with EPS near $0.00.
NIVFW Financials
Bull Case vs Bear Case
Bull Case
- NewGenIvf's recent insider buying suggests those in the know see value, similar to how insiders loaded up on Tesla before its major 2020 rally.
- Community chatter highlights positive sentiment around NewGenIvf's expansion plans, mirroring the excitement around Amazon's early growth.
- The company's focus on fertility solutions aligns with a growing global demand, much like the renewable energy sector's tailwinds.
- Positive market perception of NewGenIvf's innovative approach could lead to increased investor interest, reminiscent of the early days of biotech firms like Amgen.
Bear Case
- Some community members express concerns about increased competition in the fertility market, akin to the crowded streaming landscape.
- Recent market volatility could negatively impact NewGenIvf, similar to how the 2008 crisis affected even strong companies.
- Skeptics question the sustainability of NewGenIvf's growth rate, drawing parallels to companies with unsustainable hype cycles.
- Negative sentiment regarding potential regulatory changes could create headwinds for NewGenIvf, much like the pharmaceutical industry faces with drug pricing debates.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NIVFW Latest News
No recent news available for NIVFW.
NIVFW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NIVFW.
Price Targets
Wall Street price target analysis for NIVFW.
NIVFW MoonshotScore
What does this score mean?
The MoonshotScore rates NIVFW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Wing Fung Siu
Managing Director
Wing Fung Siu serves as the Managing Director of NewGenIvf Group Limited, overseeing the company's operations and strategic direction. His background includes extensive experience in healthcare management and business development. Wing Fung Siu is responsible for leading the company's expansion efforts and ensuring the delivery of high-quality fertility services across its network of clinics. He has a strong understanding of the assisted reproductive technology (ART) industry and is committed to providing innovative solutions to meet the needs of patients.
Track Record: Under Wing Fung Siu's leadership, NewGenIvf Group Limited has expanded its presence in multiple countries and enhanced its service offerings. He has successfully navigated the company through various challenges and opportunities, contributing to its growth and profitability. His strategic decisions have positioned NewGenIvf as a leading provider of fertility services in the region.
NIVFW Healthcare Stock FAQ
What does NewGenIvf Group Limited do?
NewGenIvf Group Limited is an investment holding company that provides assisted reproductive services to couples and individuals seeking fertility treatments. The company operates clinics in Thailand, Cambodia, Hong Kong, and Kyrgyzstan, offering a range of services, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and surrogacy. NewGenIvf aims to provide comprehensive and personalized care to its patients, helping them achieve their dream of starting a family. The company also offers value-added services such as nutrition guidance and psychological counseling to support patients throughout their fertility journey.
What are the key growth opportunities for NIVFW in healthcare?
NewGenIvf Group Limited has several growth opportunities within the healthcare sector. Expanding its geographic footprint into new markets, such as Vietnam or Indonesia, can significantly increase its patient base. Enhancing its service offerings with advanced reproductive technologies, such as preimplantation genetic testing (PGT), can attract higher-paying clients and improve success rates. Strategic partnerships with international clinics can facilitate technology transfer and patient referrals. Implementing telemedicine services can improve accessibility and reach patients in remote areas. These initiatives can drive revenue growth and strengthen NewGenIvf's position in the assisted reproductive technology (ART) market.
How does NewGenIvf Group Limited navigate regulatory approval processes?
NewGenIvf Group Limited operates in a highly regulated industry and must comply with various regulatory requirements in each of the countries where it operates. The company works closely with local regulatory authorities to ensure that its clinics and services meet all applicable standards. This includes obtaining necessary licenses and permits, adhering to ethical guidelines, and maintaining patient safety. NewGenIvf also stays informed about changes in regulations and adapts its practices accordingly to ensure compliance. The company's commitment to regulatory compliance is essential for maintaining its reputation and ensuring the long-term sustainability of its business.
What are the key factors to evaluate for NIVFW?
Evaluate NIVFW on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does NIVFW data refresh on this page?
NIVFW prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NIVFW's recent stock price performance?
NewGenIvf Group Limited (NIVFW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive range of fertility services. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NIVFW overvalued or undervalued right now?
Valuing NewGenIvf Group Limited (NIVFW) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NIVFW?
Before investing in NewGenIvf Group Limited (NIVFW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited, requiring further due diligence.
- AI analysis is pending, potentially providing additional insights.